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1.Abstract 
The potential of polycyclic aromatic hydrocarbons (PAHs) to modulate microsomal 
epoxide hydrolase activity, determined using benzo[a]pyrene 5-oxide as substrate, in 
human liver, was evaluated and compared to rat liver. Precision-cut liver slices 
prepared from fresh human liver were incubated with six structurally-diverse PAHs, 
at a range of concentrations, for 24 hours. Of the six PAHs studied, benzo[a]pyrene, 
dibenzo[a,h]anthracene and fluoranthene gave rise to a statistically significant 
increase  in epoxide hydrolase activity, which was accompanied by a concomitant 
increase in epoxide hydrolase protein levels determined by immunoblotting. The other 
PAHs studied, namely dibenzo[a,l]pyrene, benzo[b]fluoranthene and 1-
methylphenanthrene, influenced neither activity nor enzyme protein levels. When rat 
slices were incubated under identical conditions, only benzo[a]pyrene and 
dibenzo[a,h]anthracene elevated epoxide hydrolase activity, which was, once again 
accompanied by a rise in protein levels. At the mRNA level, however, all six PAHs 
caused an increase, albeit to different extent. In rat, epoxide hydroxylase activity in 
lung slices was much lower than in liver slices. In lung slices, epoxide hydrolase 
activity was elevated following exposure to benzo[a]pyrene and dibenzo[a,l]pyrene 
and, to a lesser extent, 1-methylphenanthrene; similar observations were made at the 
protein level. At both activity and protein levels extent of induction was far more 
pronounced in the lung compared with the liver. It is concluded that epoxide 
hydrolase activity is an inducible enzyme by PAHs, in both human and rat liver, but 
induction potential by individual PAHs varies enormously, depending on the nature of 
the compound involved. Marked tissue differences in the nature of PAHs stimulating 
activity in rat lung and liver were noted. Although in the rat basal lung epoxide 
hydrolase activity is much lower than liver, it is more markedly inducible by PAHs. 
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2.Introduction  
The toxicity and carcinogenicity of many chemicals, both naturally-occurring and 
anthropogenic, are inextricably linked to their metabolism to reactive, electrophilic 
intermediates that interact covalently with vital cellular macromolecules leading to 
mutations and toxicity. Such metabolites include epoxides, which have been 
implicated in the toxicity/carcinogenicity of many structurally-diverse chemicals 
including polycyclic aromatic hydrocarbons [1], mycotoxins such as aflatoxin B1 [2], 
and halogenated aliphatic compounds such as vinyl chloride [3]; their formation is 
most frequently catalysed by cytochromes P450. 
 The principal protective mechanism of the living organism is to deactivate the 
epoxides by metabolically converting them to inactive, readily excretable products. 
The two most important enzyme systems catalysing the detoxication of epoxides are 
the microsomal epoxide hydrolase [4] and the cytosolic glutathione S-transferases [5]. 
The former inserts water to the epoxide to yield a dihydrodiol, and the latter catalyses 
the conjugation of epoxides with reduced glutathione; the glutathione conjugate is 
usually further metabolically processed and is excreted as the mercapturate. In the 
case of the primary epoxides of polycyclic aromatic hydrocarbons (PAHs), however, 
microsomal epoxide hydrolase converts primary epoxides to the corresponding trans-
dihydrodiols, which are the precursors for the generation of dihydrodiol epoxides, 
following cytochrome P450-mediated oxidation, the ultimate carcinogenic species; 
these epoxides do not serve as substrates of epoxide hydrolase [6]. Consequently, 
levels of epoxide hydrolase activity play an important role in determining the fate of 
PAHs. 
 The highest concentration of the microsomal epoxide hydrolase is in the liver, 
but it is also encountered in many other tissues including the lung. Despite its high 
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level of basal expression, hepatic epoxide hydrolase activity, monitored using 
benzo[a]pyrene 4,5-oxide as substrate, in the male rat may be induced by a number of 
xenobiotics, including hepatocarcinogens such as safrole, diethylnitrosamine, 
aflatoxin B1 and 2-acetylaminofluorene [7,8]. Interestingly, in the same studies no 
increase was seen following exposure to 3-methylcholanthrene, a PAH that is a potent 
inducer of CYP1, the principal cytochrome P450 family responsible for PAH 
metabolism; similar observations have been made in mice [9]. This effect appears not 
to be tissue specific, as 3-methylcholanthrene also failed to enhance epoxide 
hydrolase activity in rat lung [10]. By contrast, studies performed using primary 
human primary hepatocyte cultures demonstrated that a number of xenobiotics could 
elicit a modest increase in epoxide hydrolase mRNA levels, although this was not 
translated to the protein level; PAHs were not investigated in this study [11]. In more 
recent studies emanating from our laboratory employing precision-cut rat liver and 
lung slices, it was demonstrated that the prototypical PAH benzo[a]pyrene was a 
modest inducer of epoxide hydrolase activity, and protein  and mRNA expression 
[12]. 
 Clearly, the information available on the modulation of microsomal epoxide 
hydrolase by PAHs, either in animals or humans, is limited and contradictory despite 
the pivotal role played by this enzyme in their bioactivation. The objective of the 
present studies were: (a) to evaluate the ability of six structurally-diverse PAHs to 
modulate rat epoxide hydrolase activity in precision-cut liver slices; (b) perform 
similar studies utilising precision-cut human liver slices so as to be able to identify 
whether a species difference in the regulation of this enzyme exists between human 
and rat, a very frequently used animal species in the evaluation of the carcinogenic 
activity of PAHs; (c) establish whether tissue-specific differences are present in the 
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regulation of this enzyme by PAHs in the rat liver and lung, the latter being a target 
tissue of their carcinogenicity and, finally, (d) compare the effects of PAHs on rat 
hepatic epoxide hydrolase and CYP1A and CYP1B expression determined under 
identical conditions [13]. Epoxide activity was monitored using one of the primary 
epoxides of benzo[a]pyrene, namely the 4,5-oxide, as substrate, and was supported by 
immunological studies employing Western blot analysis; additionally, in order to 
delineate possible mechanisms, mRNA levels were determined in some of the studies.
  
 
3.Materials and Methods 
Dibenzo[a,l]pyrene, 1-methylphenanthrene (LGC Promochem, Middlesex, UK), 
benzo[a]pyrene, fluoranthene, benzo[b]fluoranthene, dibenzo[a,h]anthracene, 
peroxidase-linked anti-rabbit antibody (Sigma Co. Ltd., Poole, Dorset, UK), 
benzo[a]pyrene 4,5-epoxide and benzo[a]pyrene 4,5-diol (Mid-West Research 
Institute, Kansas, USA), rat genomic DNA (Novagen, Wisconsin, USA), Superscript II 
(Invitrogen, Paisley, UK), RNase-free DNase (Promega, Wisconsin, USA), Qiagen RNeasy 
Mini kits (Crawley, West Sussex, UK), AbsoluteTM QPCR Mix (Abgene, Epsom, Surrey, UK)   
and Earle’s balanced salt solution (EBSS), foetal calf serum, gentamycin and RPMI 
1640 Glutamax II culture medium (Gibco-BRL Life Technologies, Paisley, Scotland) 
were all purchased. Twelve-well plates were obtained from Bibby Sterilin (Helena 
Biosciences, Sunderland). Antibody to microsomal epoxide hydrolase was a kind gift 
from Professor M Arand [14].  
Liver sections from two human cadaveric livers that could not be used for 
transplantation purposes were obtained from the UK Human Tissue Bank (The 
Innovation Centre, Oxford Street, Leicester, UK). Donor 1 was a 60-year old male 
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and Donor 2 a 57-year old female; both were Caucasian and smokers. Sections were 
received 8 - 12 hours after the liver was removed from the donor and were transported 
in cold University of Wisconsin (UW) preservation solution on ice.  On receipt, the 
liver sections were immediately transferred into a sterile container and, after the UW 
solution was carefully decanted, they were washed 3 to 4 times with culture medium.  
The metabolic viability of the two livers was evaluated using 7-ethoxycoumarin as 
substrate, following a 6-hour incubation [13]. Male Wistar albino rats (200g) were 
obtained from B&K Universal Ltd (Hull, East Yorkshire, UK). The animals were 
housed at 22 ± 2 °C, 30-40 % relative humidity in an alternating 12-hr light:dark cycle 
with light onset at 07.00 hr. Rats were killed by cervical dislocation, liver was 
immediately excised; human and rat liver slices (250 μm) were prepared from 8mm 
cylindrical cores using a Krumdieck tissue slicer (Alabama Research and 
Development Corporation, Munsford, AL, USA) as previously described [15]. The 
multiwell plate procedure, using tweleve-well culture plates, was used to culture the 
slices. The culture medium was essentially that described by Lake et al. [16] and 
comprised RPMI 1640 Glutamax II containing foetal calf serum (5%), L-methionine 
(0.5 mM), insulin (1 μM), gentamycin (50 μg/mL) and hydrocortisone 21-
hemisuccinate (0.1 mM). One slice was placed in each well, in 1.5 ml of culture 
medium. Slices were incubated under sterile conditions on a reciprocating plate 
shaker housed in a humidified incubator, at a temperature of 37 ºC and under an 
atmosphere of 95 % air/5% CO2. The slices were initially pre-incubated for 30 min in 
order to slough off any dead cells due to slicing. For the production of lung slices, 
animals were killed by an overdose of sodium pentobarbital, and lungs were perfused 
intratracheally with agarose (0.75% v/w) at 37 °C. Agar was allowed to solidify, and 
lung slices (600 μm) were prepared from cylindrical cores (8 mm) as described for the 
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liver [17]. For incubations exceeding 24 h, slices were placed in fresh medium every 
24 h. Three different slice pools, comprising 4-10 slices, were used per time point. 
Following incubation, slices were removed from the medium, homogenised, 
and microsomal fractions were prepared. Epoxide hydrolase activity was determined 
in the microsomal fraction using benzo[a]pyrene 4,5-epoxide as substrate [18];  
protein concentration was also determined [19]. Finally, in order to determine 
expression at the protein level, hepatic microsomal proteins were resolved by 
electrophoresis and incubated with antibody to epoxide hydrolase, raised in rabbit, 
and peroxidase-linked anti-rabbit antibody. Immunoblots were quantitated by 
densitometry using the GeneTool software (Syngene Corporation, Cambridge, UK). 
Two slices were pooled for total RNA extraction, and for each sample 
triplicate extractions were carried out. RNA was extracted using the Qiagen RNeasy 
Mini kit, and was quantified using a Nanodrop spectrophotometer. Total RNA was 
treated with RNase-free DNase to remove genomic contamination. Reverse 
transcription was primed with random hexamers and carried out by Superscript II 
according to the manufacturer’s instructions. To ensure that DNase treated samples 
were free from genomic contamination, an RT- control was carried out for every RNA 
sample. cDNA generated from 50ng was amplified using Absolute QPCR Mix with 
400 nM primers and 100 nM fluorogenic probe in a total reaction volume of 25μl. Q-
PCR reactions were run on an ABI7000 SDS instrument and quantitation was carried 
out using the ABI proprietary software against a standard curve generated from rat 
genomic DNA. 
For the quantitative reverse transcription-polymerase chain reaction, the 
primer and TAMRA/FAM dual labelled probe [12] were designed using the Primer 
Express software (Applied Biosystems, California, USA) and purchased from MWG, 
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Ebersberg, Germany.  Each primer and probe set was designed to amplify sequences 
within a single exon, so that genomic DNA could be used as a standard. The 
characteristics of PAH-dependent alteration in transcript levels were calculated using 
Prism v5 (GraphPad Inc, CA) to fit a one-site binding model (hyperbole) to the 
observed mRNA levels, generating Imax (maximal fold induction) and EC50 
(concentration required to achieve one-half Imax) values. 
Statistical evaluation was carried out using the Student’s t-test. 
 
4.Results 
Exposure of rat liver slices to a range of concentrations of the various PAHs resulted 
in a modest increase in activity only in the case of benzo[a]pyrene and 
dibenzo[a,h]anthracene, with maxima being achieved at about 5-10 μM (Figure 1). 
The rise in activity was accompanied by a similar increase in protein levels, detected 
immunologically, with dibenzo[a,h]anthracene being the more potent of the two 
(Figure 2). Dibenzo[a,l]pyrene led to a 40% increase in protein levels, but no 
significant effect could be detected at the activity level. No increase in protein levels 
was evident following incubation of the liver slices with benzo[b]fluoranthene, 
fluoranthene and 1-methylphenanthrene (results not shown). At the mRNA level, 
however, all compounds elevated epoxide hydrolase mRNA levels (Figure 3). EC50 
and Imax values are shown in Table 1. 
 Basal epoxide hydrolase activity in the two human livers employed in the 
present study was 3-4 times higher compared with the rat slices. When human liver 
slices were exposed to the same PAHs, under identical conditions to the rat slices, a 
similar picture emerged in that benzo[a]pyrene and dibenzo[a,h]anthracene elevated 
epoxide hydrolase activity; however, in contrast to rat liver, a significant increase in 
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activity was also observed following fluoranthene treatment (Figure 4); once again 
maxima were achieved at a concentration of 5-10 μM. The increase in activity was 
accompanied by a rise in apoprotein levels (Figure 5). Benzo[b]fluoranthene, at only 
one concentration, gave a rise to a 10% increase in activity which was statistically 
significant, but no rise in protein levels was observed at all concentrations studied 
(Figures 4 and 5). 
 Basal epoxide hydrolase activity in rat lung slices was much lower than the 
hepatic activity, by approximately one order of magnitude, and when lung slices were 
incubated with the various PAHs, under the identical conditions employed in the liver 
studies, a different induction profile emerged. Benzo[a]pyrene, 1-methylphenathrene 
and, especially, dibenzo[a,l]pyrene were potent inducers, increasing both activity 
(Figure 6) and protein levels (Figure 7). Maximal increase in activity was attained at 
about 1 μM. In contrast, neither activity nor protein levels were elevated by the 
treatment with fluoranthene or benzo[b]fluoranthene (Figures 6 and 7). Finally, 
dibenzo[a,h]anthracene caused a clear increase in apoprotein levels, but the rise in 
activity was not statistically significant. 
 
 
5.Discussion 
The use of precision-cut tissue slices to evaluate the induction potential of chemicals 
is especially advantageous when studying tissues like the lung, which comprises 
various cell types characterised with different metabolic activity. Moreover, it allows 
the study of a range of concentrations that would otherwise require large numbers of 
animals for in vivo studies. 
 10
 In the present study we investigated the ability of six structurally-diverse 
PAHs to up-regulate epoxide hydrolase activity, a key enzyme in the metabolism of 
PAHs, as well as other chemical carcinogens. These studies were conducted in rat and 
human liver, and rat lung slices. The optimal conditions of exposure, e.g. 
concentration range and incubation time, for both liver and lung slices have already 
been established [12], and were adopted in the current studies. 
 Basal activities showed clear species and tissue differences. Firstly, rat lung 
activity was much lower than in the liver, in agreement with the previous observations 
[20]. Secondly, although based on only two human livers, it appears that epoxide 
hydrolase activity in rat is about one-half of that observed in humans. This finding 
contradicts previous studies where no significant difference in activity, determined 
using the same substrate, was noted; however, the Sprague-Dawley rat was used in 
these studies [20], compared to Wistar in the current study, and strain differences may 
exist as has already been established for cytochrome P450 activities. It is pertinent to 
emphasise that both liver donors were smokers, so that epoxide hydrolase activity 
could have been in an induced state. However, since epoxide hydrolase is only a 
modestly inducible enzyme, for example in comparison with CYP1, we believe this is 
unlikely, although the possibility can not be entirely discarded. 
 Of the six PAHs studied, only benzo[a]pyrene and dibenzo[a,h]anthracene 
enhanced significantly epoxide hydrolase activity in rat liver, and the parallel rise in 
apoprotein levels suggests that increased enzyme availability is the underlying 
mechanism. To a lesser extent, exposure of the slices to dibenzo[a,l]pyrene led to a 
rise in the protein levels but this was not reflected at the activity level, perhaps due to 
the higher sensitivity of the immunological procedure. At the mRNA level, all PAHs 
studied increased epoxide hydrolase, albeit to different extent, implying 
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transcriptional activation or mRNA stabilisation as a contributory mechanism. 
However, the high epoxide hydrolase mRNA levels, as defined by Imax/EC50, and 
protein levels observed with some of the PAHs were not translated to increased 
activity. Lack of concordance between epoxide hydrolase mRNA and protein levels 
has already been reported following exposure of human primary hepatocytes to 
chemical inducers [11]. Furthermore, lack of correlation between mRNA levels and 
activity has been documented with many enzymes, and it has been proposed that a 
threshold exists that has to be exceeded in order for mRNA to be translated, so that 
activation of the gene at the mRNA level does not always lead to higher protein levels 
[21]. However, the fact the mRNA levels were monitored in the complete slice but 
activity/protein in the isolated microsomes could have contributed to this lack of 
correlation as translation products of mRNA could have been missed. Moreover, as 
mRNA levels were monitored only at a single time point differences in temporal 
response may be partly responsible. Of interest is also the fact that a number of 
independent regulatory regions have been identified in the epoxide hydrolase gene 
[4], and it is conceivable that the various PAHs act at different transcriptional units. 
Benzo[a]pyrene enhanced epoxide hydrolase activity but it was a weak inducer of 
epoxide hydrolase mRNA levels. It may be cautiously inferred that transcriptional 
activation may not be the major mechanism for the induction of epoxide hydrolase, 
and that (post)transcriptional processes, such as translation efficiency or protein 
stabilisation, may be largely responsible.  
 In the 1980s a number of studies failed to show induction of hepatic epoxide 
hydrolase activity, either in the rat or mouse, by 3-methylcholanthrene which at the 
time was the model PAH employed in induction studies. Clearly, what the present 
studies have shown is that individual PAHs have the potential to induce this enzyme, 
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and one can not generalise on the basis of studies with single compounds. It is also 
pertinent to point out that the rise in activity is very modest compared with the effects 
of the same compounds on CYP1 activity monitored by the O-deethylation of 
ethoxyresorufin [13]. Moreover, CYP1 and epoxide hydrolase induction by individual 
PAHs appears to involve different regulation pathways, CYP1 being regulated by the 
aryl hydrocarbon receptor. For example, benzo[b]fluoranthene was the most potent 
inducer of CYP1 activity among the six studied PAHs whereas it failed to influence 
epoxide hydrolase activity. It is likely that the formation of the dihydrodiol epoxides 
would be enhanced if epoxide hydrolase was also upregulated, in addition to CYP1, 
as this would facilitate the conversion of the primary epoxides to the dihydrodiol, the 
precursor of the dihydrodiol epoxide.  Indeed the formation of benzo[a]pyrene 
dihydrodiol-epoxide-DNA adducts in the presence of 3-methylcholanthrene-induced 
rat liver microsomes was markedly enhanced when the activation system was 
supplemented with purified epoxide hydrolase [22].  
 Human epoxide hydrolase activity was similarly elevated following exposure 
to the six PAHs, the extent of induction being similar to that observed in the rat. In 
both species, benzo[a]pyrene and dibenzo[a,h]anthracene increased activity, but 
fluoranthene also enhanced the activity in the human slices only. As noted in rat liver, 
the rise in activity was accompanied by a similarly modest rise in protein levels, 
suggesting that enhanced enzyme synthesis and/or enzyme stabilisation is the 
underlying mechanism for these effects.  
 Although epoxide hydrolase activity in the rat lung was lower than in the liver, 
it was more inducible in both activity and, in particular, protein level. Substantial 
variation in the epoxide hydrolase activity was evident between lung slices, which 
most likely reflect the fact that the lung, in contrast to the liver, has a heterogeneous 
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cell population, and enzyme activity may not be uniformly distributed in all cell types 
[4]. Moreover, the profile of induction by the six PAHs in the lung differed to that 
seen in the liver in that, in addition to benzo[a]pyrene, the pulmonary activity was 
also enhanced by 1-methylphenanthrene and dibenzo[a,l]pyrene, the latter being the 
most potent of the six PAHs studied. As noted in the liver, changes in activity were 
associated with similar changes in immunologically-determined epoxide hydrolase 
protein levels. Moreover, peak induction in the lung slices by PAHs occurred at 
concentrations of about 1 μM, one tenth of those required for maximal induction in 
the liver. A possible contributory factor to this difference may be, at least in part, the 
higher rate of metabolic breakdown of PAHs in the liver compared with lung, leading 
to a rapid decline in its effective concentration; the rate of metabolism of 
benzo[a]pyrene to phenolic products in liver slices is markedly higher compared with 
lung slices (unpublished observations). At concentrations higher than 1 μM, the 
inductive effect of PAHs dropped to control values; a similar picture was noted when 
the induction of CYP1 was studied under identical conditions [13] 
An interesting observation is that, in the lung, dibenzo[a,l]pyrene, a highly 
carcinogenic compound more active than benzo[a]pyrene, was the most potent 
inducer of epoxide hydrolase. In contrast, relative to other PAHs it is a weak inducer 
of CYP1A in both the lung and liver and does not modulate CYP1B1 expression in 
the lung [13]. As the addition of purified epoxide hydrolase to hepatic microsomes 
enhanced the generation of the benzo[a]pyrene dihydrodiol epoxide   [22], implying 
that it may be rate limiting, it is tempting to speculate that the ability of 
dibenzo[a,l]pyrene to stimulate pulmonary epoxide hydrolase, which is present at 
lower levels in the lung compared with the liver, may contribute in part to its high 
carcinogenic activity. It is relevant to point out that following systemic exposure to 
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dibenzo[a,l]pyrene, the majority of DNA adducts in the lung were derived from the 
dihydrodiol-epoxide [23]. 
 In summary, employing precision-cut slices in vitro, we have demonstrated 
that rat microsomal epoxide hydrolase is an enzyme inducible by PAHs, albeit to a 
much lesser extent compared with CYP1. No correlation was evident between 
induction of CYP1 and epoxide hydrolase, implying different regulatory control. 
Although lung epoxide hydrolase activity in the rat is lower than in the liver, it 
appears to be more sensitive to induction by PAHs. The induction profile by the six 
PAHs studied differed in the two tissues, revealing tissue-specific differences. 
Epoxide hydrolase was also inducible in the human liver, with a similar profile to that 
in rat liver. To our knowledge this is the first study establishing induction of epoxide 
hydrolase in human tissue. 
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Table 1: Parameters defining the PAH-dependent effect on epoxide hydrolase 
mRNA levels 
 
Parameters were calculated using Prism v5 (GraphPad Inc, CA) to fit a one-site 
binding model (hyperbole) to the observed mRNA levels.  
 
PAH  EC50 Imax Imax/EC50 
Benzo[a]pyrene 1.2 4.8 4.0 
Dibenzo[a,h]anthracene 0.16 6.0 37.5 
Fluoranthene  0.59 11.0 18.6 
Benzo[b]fluoranthene 0.21 6.3 30.0 
Dibenzo[a,l]pyrene 0.63 8.5 13.5 
1-methylphenanthrene 5.1 7.7 1.51 
Imax, maximal fold induction; EC50, concentration required to achieve one-half Imax. 
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Legends to figures  
Figure 1: Concentration-dependent induction of epoxide hydrolase activity by 
PAHs in precision-cut rat liver slices. 
 
Precision-cut rat liver slices were incubated in the absence and presence of the various 
PAHs, dissolved in DMSO, at a range of concentrations (0-100 μM) for 24 hours. At 
the end of the incubation period, slices were removed from the media, microsomes 
prepared and epoxide hydrolase activity determined. Results are expressed as mean ± 
SD of triplicate pools of slices. 
* P<0.05; ** P<0.01; *** P<0.001 
Benzo[a]pyrene data from Pushparajah et al (2007) 
Figure 2: Concentration-dependent induction of epoxide hydrolase protein levels 
by PAHs in precision-cut rat liver slices 
 
Precision-cut rat liver slices were incubated in the absence and presence of PAHs (0-
100 μM) for 24 hours. At the end of this period, slices were removed from the media 
and pooled, solubilised microsomal proteins were prepared and resolved by SDS-
PAGE before being transferred electrophoretically to nitrocellulose paper. 
Immunoblot was carried out using anti-rat epoxide hydrolase followed by peroxidase-
labelled anti-rabbit IgG; all lanes were loaded with 5 μg of protein. Figures above the 
immunoblot represent percentage values compared with control (DMSO-treated) 
slices which were set at 100%.  
Benzo[a]pyrene data from Pushparajah et al (2007) 
 
 
Figure 3: Concentration-dependent changes in epoxide hydrolase mRNA levels 
in precision-cut rat liver slices incubated with PAHs. 
 
Precision-cut rat liver slices were incubated in the absence and presence of the various 
PAHs, dissolved in DMSO, at a range of concentrations for 24 hours. At the end of 
the incubation period, slices were removed from the media and total RNA extracted. 
Epoxide hydrolase mRNA levels were determined by quantitative RT-PCR 
(TaqMan). Changes are shown as fold-increases compared to control slices incubated 
with DMSO only. Results are expressed as mean ± SD where n=4. 
P<0.05; ** P<0.01 
Benzo[a]pyrene data from Pushparajah et al (2007) 
 
Figure 4: Concentration-dependent induction of epoxide hydrolase activity by 
PAHs in precision-cut human liver slices. 
 
Precision-cut human liver slices were incubated in the absence and presence of the 
various PAHs, dissolved in DMSO, at a range of concentrations (0-50 μM) for 24 
hours. At the end of the incubation period, slices were removed from the media, 
microsomes prepared and epoxide hydrolase activity determined. Results are 
expressed as mean ± SD of triplicate pools of slices. 
* P<0.05; ** P<0.01; *** P<0.001 
 21
 
 
Figure 5: Concentration-dependent induction of epoxide hydrolase protein levels 
by PAHs in precision-cut human liver slices 
 
Precision-cut human liver slices were incubated in the absence and presence of PAHs 
(0-50 μM) for 24 hours. At the end of this period, slices were removed from the media 
and pooled, solubilised microsomal proteins were prepared and resolved by SDS-
PAGE before being transferred electrophoretically to nitrocellulose paper. 
Immunoblot was carried out using anti-rat epoxide hydrolase followed by peroxidase-
labelled anti-rabbit IgG; all lanes were loaded with 5 μg of protein. Figures above the 
immunoblot represent percentage values compared with control (DMSO-treated) 
slices which were set at 100%. 
 
 
Figure 6: Concentration-dependent induction of epoxide hydrolase activity by 
PAHs in precision-cut rat lung slices. 
 
Precision-cut rat lung slices were incubated in the absence and presence of the various 
PAHs, dissolved in DMSO, at a range of concentrations (0-5 μM) for 24 hours. At the 
end of the incubation period, slices were removed from the media, microsomes 
prepared and epoxide hydrolase activity determined. Results are expressed as mean ± 
SD of triplicate pools of slices. 
* P<0.05; ** P<0.01 
Benzo[a]pyrene data from Pushparajah et al (2007) 
 
 
Figure 7: Concentration-dependent induction of epoxide hydrolase protein levels 
by PAHs in precision-cut rat lung slices 
 
Precision-cut rat lung slices were incubated in the absence and presence of PAHs (0-5 
μM) for 24 hours. At the end of this period, slices were removed from the media and 
pooled, solubilised microsomal proteins were prepared and resolved by SDS-PAGE 
before being transferred electrophoretically to nitrocellulose paper. Immunoblot was 
carried out using anti-rat epoxide hydrolase followed by peroxidase-labelled anti-
rabbit IgG. Figures above the immunoblot represent percentage values compared with 
control (DMSO-treated) slices which were set at 100%. With the exception of 
fluoranthene and benzo[b]fluoranthene where the same amount of protein was applied 
in all wells, with the other PAHs twice the amount of protein was added in the case of 
the control animals; a correction has already been applied in the quantitation data. 
Benzo[a]pyrene data from Pushparajah et al (2007) 
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